No Data
No Data
No Data
The Three-year Shareholder Returns and Company Earnings Persist Lower as Jafron BiomedicalLtd (SZSE:300529) Stock Falls a Further 6.7% in Past Week
Jafron Biomedical: 2024 Interim Performance Forecast
Jafron BiomedicalLtd (SZSE:300529) Could Be Struggling To Allocate Capital
A Look At The Fair Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)
Jafron Biomedical (300529.SZ) : Currently, all production capacity construction projects are being orderly carried out according to plan.
Jafron Biomedical (300529.SZ) stated on the investor interaction platform on June 19th that all production capacity construction projects of the company are progressing in an orderly manner according to the plan. At present, the company's production capacity can meet the development needs of its business, and the utilization rate of production capacity is in a reasonable range.
Jafron Biomedical (300529.SZ): specializes in research and development, production, and sales of biomedical materials and high-tech medical instruments.
Jafron Biomedical (300529.SZ) stated on the investor interaction platform on June 19 that the company specializes in the research and development, production and sales of biomaterials and high-tech medical instruments. Its main products, blood perfusion devices, mainly uses medical resin as an adsorbent to achieve specific adsorption of large-molecule toxins and protein-bound toxins in the blood. It is widely used in the treatment of uremia, poisoning, severe liver disease, multiple organ failure, etc., and can effectively save patients' lives or improve their quality of life.
No Data